Year: 2026
Type: editorial
Abstract: Recent psychedelic patent activity highlights a strategic shift from experiential framing toward chemically and pharmacokinetically precise neurotherapeutics. Four recent patent applications collectively span solid-state control of psilocybin, exposure-shaped intramuscular and infusion-based dosing, and chemically diversified monoaminergic scaffolds with defined transporter and receptor pharmacology. Together, these disclosures outline a platform-level evolution toward reproducible, mechanism-informed psychedelic medicines.
Source: ACS Medicinal Chemistry Letters
Authors: Anna C. Renner, Robert B. Kargbo
Institution: North Dakota State University
Language: English
Subfield: Clinical Psychology
Field: Psychology
Domain: Social Sciences
Open Access status: bronze
OpenAlex ID: W7122597626